`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`TEVA PHARMACEUTICALS USA, INC. AND WATSON
`LABORATORIES, INC.
`Petitioners,
`v.
`MERCK SHARP & DOHME CORP.
`Patent Owner.
`_______________
`Case IPR2020-01045
`Patent 7,326,708
`_______________
`
`PETITIONERS’ UPDATED MANDATORY NOTICES
`
`
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`Case IPR2020-01045
`Patent No. 7,326,708
`
`
`Pursuant to 37 CFR § 42.8(b)(3), Petitioners Teva Pharmaceuticals USA, Inc.
`
`and Watson Laboratories, Inc. hereby file the following Updated Mandatory
`
`Notices.1
`
`A. Each Real Party in Interest (37 C.F.R. § 42.8(b)(1))
`The following real parties in interest are identified: Teva Pharmaceutical
`
`Industries, Ltd., Teva Pharmaceuticals USA, Inc., and Watson Laboratories, Inc.
`
`B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))
`1.
`Judicial Matters Involving the ’708 Patent
`The ’708 patent is currently the subject of the following litigations: Merck
`
`Sharp & Dohme Corp. v. Aurobindo Pharma Limited et al., 1-20-cv-00949 (D. Del.);
`
`Merck Sharp & Dohme Corp. v. Dr. Reddy's Laboratories, Inc. et al.; 1-20-cv-00847
`
`(D. Del.); Merck Sharp & Dohme Corp. v. Ajanta Pharma Limited et al., 1-20-cv-
`
`00815 (D. Del.); Merck Sharp & Dohme Corp. v. Lupin Limited et al., 1-20-cv-
`
`00776 (D. Del.); Merck Sharp & Dohme Corp. v. Apotex Inc. et al., 1-20-cv-00749
`
`(D. Del.); Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Ltd. et al., 1:19-
`
`cv-00872 (D. Del.)2; Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc.
`
`et al., 1:19-cv-00101 (N.D. W.Va.); Merck Sharp & Dohme Corp. v. Mylan
`
`
`1 Petitioners’ mandatory notices are updated to reflect the admission pro hac vice of
`Ms. Rapalino (see Paper 15).
`2 This case was terminated pursuant to a consent judgment entered on February 19,
`2020.
`
`1
`
`
`
`Case IPR2020-01045
`Patent No. 7,326,708
`
`Pharmaceuticals Inc. et al., 1:19- cv-01489 (D. Del.); Merck Sharp & Dohme Corp.
`
`v. Alvogen Pine Brook f/k/a Alvogen Pine Brook, Inc. et al., 1:19-cv-00310 (D.
`
`Del.)3; Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals, Inc. et al., 1:19-
`
`cv-00311 (D. Del.); Merck Sharp & Dohme Corp. v. Sandoz, Inc., 1:19-cv-00312
`
`(D. Del.); Merck Sharp & Dohme Corp. v. Apotex Inc. et al., 1:19-cv-00313 (D.
`
`Del.); Merck Sharp & Dohme Corp. v. Zydus Pharmaceuticals (USA) Inc. et al.,
`
`1:19-cv-00314
`
`(D. Del.); Merck Sharp & Dohme Corp. v. Macleods
`
`Pharmaceuticals, Ltd. et al., 1:19-cv-00316 (D. Del.)4; Merck Sharp & Dohme Corp.
`
`v. Watson Pharmaceuticals, Inc. et al., 1:19-cv-00317 (D. Del.); Merck Sharp &
`
`Dohme Corp. v. Teva Pharmaceuticals USA, Inc., 1:19-cv-00318 (D. Del.); Merck
`
`Sharp & Dohme Corp. v. Sun Pharma Global FZE et al., 1:19-cv-00319 (D. Del.);
`
`Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Limited et al., 1:19-cv-
`
`00320 (D. Del.)5; Merck Sharp & Dohme Corp. v. Wockhardt Bio AG et al., 1:19-
`
`cv-00321 (D. Del.)6; Merck Sharp & Dohme Corp. v. Lupin Ltd. et al., 1:19-cv-
`
`00347 (D. Del.); Merck Sharp & Dohme Corp. v. Accord Healthcare, Inc., 1:19-cv-
`
`
`3 This case was terminated pursuant to a consent judgment entered on July 16, 2020.
`4 This case was terminated pursuant to a consent judgment entered on April 28, 2020.
`5 This case was terminated pursuant to a consent judgment entered on February 19,
`2020.
`6 This case was terminated pursuant to a consent judgment entered on May 28, 2020.
`
`2
`
`
`
`Case IPR2020-01045
`Patent No. 7,326,708
`
`02192 (D. Del.)7; Merck Sharp & Dohme Corp. v. Apotex Inc., 1:20-cv-749 (D. Del.)
`
`and In re Sitagliptin Phosphate (’708 & ’921) Patent Litigation, C.A. No. 19-md-
`
`2902-RGA (D. Del.).
`
`2.
`Administrative Matters
`The Public Patent Application Information Retrieval (PAIR) website indicates
`
`that there are no related United States patents or pending applications. The ’708
`
`patent is currently the subject of the following inter partes reviews: Mylan
`
`Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp., IPR2020-00040 (P.T.A.B.);
`
`Dr. Reddy’s Laboratories, Inc. v. Merck Sharp & Dohme Corp., IPR2020-01060
`
`(P.T.A.B.); Sun Pharmaceuticals Industries Ltd. v. Merck Sharp & Dohme Corp.,
`
`IPR2020-01072 (P.T.A.B.).
`
`C. Designation of Lead and Back-Up Counsel and Service (37 C.F.R.
`§§ 42.8(b)(3), 42.8(b)(4))
`Lead Counsel
`Keith A. Zullow
`(Reg. No. 37,975)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`kzullow@goodwinprocter.com
`Tel: 212-813-8846
`Fax: 646-558-4226
`
`Back-Up Counsel
`Sarah J. Fischer
`(Reg. No. 74,104)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`sfischer@goodwinprocter.com
`Tel: 617-570-3908
`Fax: 617-801-8991
`
`
`
`7 This case was terminated pursuant to a consent judgment entered on March 27,
`2020.
`
`3
`
`
`
`Case IPR2020-01045
`Patent No. 7,326,708
`
`
`
`Additional Back-Up Counsel
`
`Emily L. Rapalino
`(admitted pro hac vice)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`erapalino@goodwinprocter.com
`Tel: 617-570-1938
`Fax: 617-801-8991
`
`
`Pursuant to 37 C.F.R. § 42.8(b)(4), counsel for Petitioner agrees to service by
`
`mail as detailed above and to electronic service by email to the email addresses
`
`above.
`
`
`Dated: August 20, 2020
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/ Keith A. Zullow /
`Keith A. Zullow (Reg. No. 37,975)
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`Tel: 212-813-8800
`Fax: 212-355-3333
`
`
`4
`
`
`
`Case IPR2020-01045
`Patent No. 7,326,708
`
`
`CERTIFICATION OF SERVICE ON PATENT OWNER
`Pursuant to 37 C.F.R. §§ 42.6(e), the undersigned certifies service of the
`
`foregoing Petitioner’s Updated Mandatory Notices on the counsel of record for the
`
`Patent Owner via electronic mail to the following addresses:
`
`Stanley E. Fisher
`Jessamyn S. Berniker
`Bruce R. Genderson
`Alexander S. Zolan
`Elise M. Baumgarten
`Shaun P. Mahaffy
`Anthony H. Sheh
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`sfisher@wc.com
`jberniker@wc.com
`bgenderson@wc.com
`azolan@wc.com
`ebaumgarten@wc.com
`smahaffy@wc.com
`asheh@wc.com
`MerckSitagliptin@wc.com
`
`
`
`/ Keith A. Zullow /
`Keith A. Zullow (Reg. No. 37,975)
`
`
`5
`
`
`Dated: August 20, 2020
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
